DongKoo Bio & Pharma’s Cho Yong Joon keeps 37.18% stake; pledged shares edge down to 26.52%

Bitget2026/10/08 08:35

DongKoo Bio & Pharma’s controlling shareholder Cho Yong Joon kept his stake unchanged at 10,604,678 shares, or 37.18%, as of Oct. 7. Shares under pledge contracts edged down to 7,565,698 shares, or 26.52%, from 7,567,885 shares, or 26.53%. The filing cited partial repayment of collateralized loans as the reason for the change, with the obligation triggered on Sept. 30. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DongKoo Bio & Pharma Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008000585), on October 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail

Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

智通财经•2026/11/09 07:32

Canaccord Genuity: Lowers Oklo's target price to $66

格隆汇•2026/11/09 07:01

Bernstein: Huang Renxun's Controversy May Increase Nvidia's Regulatory Risks, but Maintains $400 Price Target

Cointime•2026/11/09 06:43

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41